全文获取类型
收费全文 | 209篇 |
免费 | 22篇 |
专业分类
基础医学 | 6篇 |
临床医学 | 7篇 |
内科学 | 20篇 |
特种医学 | 1篇 |
外科学 | 54篇 |
综合类 | 5篇 |
药学 | 4篇 |
肿瘤学 | 134篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 9篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 2篇 |
2014年 | 8篇 |
2013年 | 8篇 |
2012年 | 22篇 |
2011年 | 10篇 |
2010年 | 6篇 |
2009年 | 4篇 |
2008年 | 16篇 |
2007年 | 10篇 |
2006年 | 13篇 |
2005年 | 14篇 |
2004年 | 13篇 |
2003年 | 16篇 |
2002年 | 12篇 |
2001年 | 11篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1981年 | 1篇 |
排序方式: 共有231条查询结果,搜索用时 62 毫秒
1.
2.
Glenn Liu David R Gandara Primo N Lara Derek Raghavan James H Doroshow Przemyslaw Twardowski Philip Kantoff William Oh KyungMann Kim George Wilding 《Clinical cancer research》2004,10(3):924-928
PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor with preclinical activity against prostate cancer cell lines. A Phase II trial was conducted to determine the activity of flavopiridol in patients with metastatic hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: A total of 36 patients was enrolled from several institutions and treated with a 72-h continuous infusion of flavopiridol every 14 days at the eventual starting dose of 40 mg/m(2)/day. Dose escalation up to 60 mg/m(2)/day was permitted if no significant toxicity was observed. Responses were assessed every 12 weeks. Only those patients completing four courses of the 72-h infusion were considered evaluable for response because the primary objective was to determine progression-free survival at 6 months given the cytostatic nature of the agent. RESULTS: This study was conducted in a two-stage fashion. During the first stage, at least 20 evaluable patients needed to be enrolled to assess response. There were 22 of 36 patients evaluable for response. No objective responses were observed. Only 4 patients had stable disease for 16, 26, 29, and 48 weeks, respectively, stopping the trial by design as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. The most common toxicities were diarrhea (grade 1 and 2) and nausea, although some grade 3 and 4 diarrhea (11 and 6%, respectively) were evident. CONCLUSIONS: Flavopiridol has disappointing single-agent activity in hormone-refractory prostate cancer when administered at this dose and schedule. Its use in prostate cancer should be reserved for evaluation in combination therapies or alternative schedules. 相似文献
3.
James A Talcott Judithy Manola Jack A Clark Irving Kaplan Clair J Beard Sonya P Mitchell Ronald C Chen Michael P O'Leary Philip W Kantoff Anthony V D'Amico 《Journal of clinical oncology》2003,21(21):3979-3986
PURPOSE: Understanding the distinctive patterns of treatment-related dysfunction after alternative initial treatments for early prostate cancer (PC) may improve patients' choice of treatment and later help them adjust to its consequences. We characterized the time course of treatment complications while adjusting for potentially confounding pretreatment factors hindering other observational studies. PATIENTS AND METHODS: In a prospective cohort study of 417 men we assessed urinary, bowel, and sexual function from before primary treatment to 24 months after. To control for potential confounding, we measured sociodemographic and PC prognostic factors, medical comorbidity, and pretreatment function commonly affected by PC and its treatment. RESULTS: Patients who underwent external beam radiotherapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT) differed significantly in sociodemographic factors, cancer prognostic factors, and pretreatment symptom status, especially sexual function. Urinary incontinence increased sharply after RP, while bowel problems and urinary irritation/obstruction rose after EBRT and BT. Sexual dysfunction increased in all patients, particularly after radical prostatectomy, and nerve-sparing surgical technique had little apparent benefit. There was no change in urinary function and little change in overall bowel function after 12 months, but the time course of sexual dysfunction varied by treatment and, for bowel function, by symptom. Multiple regression modeling confirmed that treatment influences all 24-month outcomes, but residual confounding persisted. CONCLUSION: Pretreatment function and the primary treatment modality for early stage PC strongly predict the affected organ systems and time course of dysfunction. With this information, patients and their physicians may refine their choice of treatment and better anticipate its consequences. 相似文献
4.
5.
6.
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. 总被引:37,自引:8,他引:37
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
8.
9.
Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. 总被引:1,自引:0,他引:1
Matthew H McIntyre Philip W Kantoff Meir J Stampfer Lorelei A Mucci Diane Parslow Haojie Li J Michael Gaziano Miyako Abe Jing Ma 《Cancer epidemiology, biomarkers & prevention》2007,16(11):2233-2236
BACKGROUND: Experimental evidence has suggested that estrogen receptor alpha (coded by the gene ESR1) might increase prostate cancer risk, whereas estrogen receptor beta (coded by the gene ESR2) might reduce prostate cancer risk. METHODS: We investigated the relationship with prostate cancer risk of both a TA repeat polymorphism in the ESR1 5' region, ESR1 (TA)(n), and with a CA repeat polymorphism in intron 5 of ESR2, ESR2 (CA)(n), in a case-control study (545 cases and 674 controls) nested in the Physicians' Health Study. RESULTS: Prostate cancer risk was highest for carriers of ESR1 (TA)(24) and ESR1 (TA)(25). Replacing one modal ESR1 (TA)(14) allele with one ESR1 (TA)(24) allele yielded an odds ratio of 1.42 (95% confidence interval, 1.00-2.00; P=0.05). Replacing one ESR1 (TA)(14) allele with one ESR1 (TA)(25) allele yielded an odds ratio of 2.10 (95% confidence interval, 1.15-3.84; P=0.02). ESR2 (CA)(n) showed no effects on prostate cancer risk. CONCLUSIONS: The ESR1 (TA)(n) polymorphism might play a role in prostate cancer risk. 相似文献
10.